News Quantified

Stock Stats

News Stats


All News	{{AllNewsCount}}
News Wires	{{NewsWiresCount}}
Media Monitoring	{{MoreOverCount}}
SEC Edgar Filings	{{SecEdgarFilingsCount}}
Upgrades	{{UpgradesCount}}
Downgrades	{{DowngradesCount}}
Initiated	{{InitiatesCount}}
Reiterated	{{ReiteratesCount}}
Last Earnings	{{LastEarnings}}
Last Earnings EPS	{{LastEps}}
Next Earnings	{{NextEarnings}}

Order Stats

Sub-Penny
{{SubPennyStr}}
Odd Lot
{{OddLotStr}}
Avg. bid-ask spread

{{GetAvgBidAskSpreadForScale}}
Avg. bid / ask size
{{GetAvgBidSizeForScale}} {{GetAvgAskSizeForScale}}

Shares at ask / bid
{{SharesAtAsk_AMP_Str}} {{SharesAtBid_AMP_Str}}
Off exchange
{{OffExchange}}

News

Evommune (EVMN) had its "outperform" rating reaffirmed by Royal Bank Of Canada. They now have a $48.00 price target on the stock.

Evommune (EVMN) is now covered by Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $50.00 price target on the stock.

Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine [Yahoo! Finance]

Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine

Evommune (EVMN) was upgraded by Clear Str Llc to "strong-buy".

Oppenheimer Holdings, Inc.

Form 4 Evommune, Inc. For: Apr 16 Filed by: Patel Jeegar Pravinkumar

Form 4 Evommune, Inc. For: Apr 16 Filed by: Bauer Eugene

Form 4 Evommune, Inc. For: Apr 16 Filed by: Carver Kyle

Form 4 Evommune, Inc. For: Apr 16 Filed by: Drew Janice Suzann

Form 4 Evommune, Inc. For: Apr 16 Filed by: Moss Gregory S.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}